|Over a month ago|
Cyclacel Pharmaceuticals reports Q1 EPS ($1.48), consensus (49c) » 16:3605/1205/12/21
As of March 31, cash and…
As of March 31, cash and cash equivalents totaled $47.8M, compared to $33.4M as of December 31, 2020. The increase of $14.4M was primarily due to $18M of net cash provided by financing activities, offset by net cash used in operating activities of $3.6M. There were no revenues for each of the three months ended March 31, 2021 and 2020. "During the quarter, we have made significant progress in bringing our two oral targeted development candidates into mid-stage clinical development. Following recent FDA authorization of our IND for oral fadraciclib, we will finalize contract discussions with sites and open our multi-cohort Phase 1b/2 study in patients with solid tumors," said Spiro Rombotis, president and CEO. "We believe fadraciclib is establishing a strong position among compounds in clinical development that specifically address cancer resistance mechanisms, including suppression of MCL1, MYC and cyclin E. A recent publication identified potential utility of CDK9 inhibitors in KRAS mutant colorectal cancer, one of the tumor types in our study. Together with our oral CYC140 PLK1 inhibitor program, which has shown in preclinical models that KRAS mutant cancers are sensitive to CYC140 inhibition, we hope to provide valuable alternatives to patients with these difficult to treat malignancies. After strengthening our balance sheet in the quarter, we are executing a precision medicine strategy to achieve multiple milestones and data read outs over the next two years."
Fly Intel: Top five analyst initiations » 09:5604/3004/30/21
DKNG, SIOX, NRIX, CYCC, CSTL
Catch up on today's…
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. DraftKings (DKNG) initiated with a Buy at Guggenheim. 2. Sio Gene Therapies (SIOX) initiated with a Buy at H.C. Wainwright. 3. Nurix Therapeutics (NRIX) initiated with an Outperform at RBC Capital. 4. Cyclacel Pharmaceuticals (CYCC) initiated with an Outperform at Oppenheimer. 5. Castle Biosciences (CSTL) initiated with a Buy at Lake Street. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
Cyclacel Pharmaceuticals initiated with an Outperform at Oppenheimer » 06:2404/3004/30/21
Oppenheimer analyst Kevin…
Oppenheimer analyst Kevin DeGeeter initiated coverage of Cyclacel Pharmaceuticals with an Outperform rating and $17 price target, citing the potential of fadraciclib CDK2/9 inhibitor in treatment of MCL-1 dependent tumors, the expectation for oral formulation of fadraciclib to support timely enrollment for expansion cohorts in solid tumor and hematology populations, an improved AE profile with oral vs. IV, and the opportunity for CYC140 differentiation from other PLK1 inhibitors based on single agent development path. DeGeeter views fadraciclib as a potential first-in-class opportunity and believes Cyclacel can fund operations into 1H23, the analyst tells investors in a research note.
Cyclacel Pharmaceuticals initiated with an Outperform at Oppenheimer » 16:1104/2904/29/21
Oppenheimer analyst Kevin…
Oppenheimer analyst Kevin DeGeeter initiated coverage of Cyclacel Pharmaceuticals with an Outperform rating and $17 price target.
new option listings and three option delistings on April 21st » 08:3004/2104/21/21
APP, BSPE, CFB, CHRA, CTEC, CYCC, DFNS, FARM, FSTX, GENI, GNPK, IDEV, INFU, JOAN, MAX, NVVE, OBLG, PSI, SCPH, SMIN, SNSR, WKEY, XFOR, ZKIN, CBPO, DMYD, IPHI
New option listings for…
New option listings for April 21st include First Trust RBA American Industrial Renaissance (AIRR), Applovin Corporation (Class A Stock) (APP), Bespoke Capital Acquisition Corporation (Class A Stock) (BSPE), CrossFirst Bankshares Inc (CFB), Charah Solutions Inc (CHRA), Global X CleanTech ETF (CTEC), Cyclacel Pharmaceuticals (CYCC), LGL Systems Acquisition Corp (Class A Stock) (DFNS), iShares Emerging Markets Dividend (DVYE), iShares MSCI Emerging Markets Asia (EEMA), Farmer Bros. (FARM), F star Therapeutics Inc (FSTX), First Trust Nasdaq Oil and Gas (FTXN), First Trust Nasdaq Bank (FTXO), First Trust Nasdaq Transportation (FTXR), First Trust Small Cap Core AlphaDEX Fund (FYX), Genius Sports Limited (GENI), Genesis Park Acquisition Corp (Class A Stock) (GNPK), iShares Core MSCI International Developed Markets ETF (IDEV), InfuSystem (INFU), iShares Russell Top 200 Growth (IWY), iShares US Consumer Services (IYC), iShares US Consumer Goods (IYK), JOANN Inc (JOAN), MediaAlpha Inc (Class A Stock) (MAX), Nuvve Holding Corporation (NVVE), Oblong Inc (OBLG), PowerShares Dynamic Semiconductors Portfolio (PSI), scPharmaceuticals Inc (SCPH), iShares MSCI India Small Cap ETF (SMIN), Global X Internet of Things Thematic (SNSR), Soaring Eagle Acquisition Corporation (Units) (SRNGU), iShares Core US REIT ETF (USRT), Vanguard International Dividend Appreciation ETN (VIGI), WISeKey International Holdings SA (ADR) (WKEY), X4 Pharmaceuticals Inc (XFOR), and ZK International Group Co Ltd (ZKIN). Option delistings effective April 21st include China Bioligic Products Holdings Inc (CBPO), dMY Technology Group Inc II (Class A Stock) (DMYD), and Inphi Corporation (IPHI).
|Over a quarter ago|
Cyclacel Pharmaceuticals 1.807M share Spot Secondary priced at $7.00 » 08:3303/1203/12/21
Oppenheimer acted as lead…
Oppenheimer acted as lead book running manager for the offering.
Cyclacel Pharmaceuticals files to sell common stock, no amount given » 16:0203/1103/11/21
Oppenheimer & Co.…
Oppenheimer & Co. Inc. is acting as the sole book-running manager for the public offering.
Cyclacel Pharmaceuticals announces 2021 key business objectives » 08:4201/1101/11/21
Key Business Objectives…
Key Business Objectives for 2021: First patient dosed with oral fadraciclib in Phase 1/2 advanced solid tumor study; First patient dosed with oral CYC140 in Phase 1/2 advanced solid tumor study; Manufacture clinical supplies of fadraciclib and CYC140 for registration-enabling studies; Data on safety and antileukemic activity from the i.v. fadraciclib-venetoclax Phase 1 study in relapsed/refractory AML and CLL; Data from the sapacitabine-venetoclax Phase 1/2 study in relapsed/refractory AML or MDS; Initial data from the CYC140 Phase 1 First-in-Human study in patients with advanced leukemias; Data from the Phase 1b/2 IST of sapacitabine-olaparib combination in patients with BRCA mutant metastatic breast cancer when reported by the investigators.
Cyclacel Pharmaceuticals expects capital to fund operations to early 2023 » 08:4101/1101/11/21
Cyclacel Pharmaceuticals provided a business update reviewing 2020 achievements and outlining the Company's key business objectives for 2021. The Company will present at Biotech Showcase Digital 2021 taking place virtually from January 11 to 15 with a prerecorded session of the company presentation. Spiro Rombotis, President & Chief Executive Officer, will provide an overview of the Company and progress in key programs. Cyclacel will host one-on-one meetings with investors and industry stakeholders during the event. Registered Biotech Showcase Digital 2021 attendees may request one-on-one meetings with Cyclacel through the partneringONE system. 2020 Key Achievements: Data from Phase 1 study of fadraciclib as a single agent reported at the Plenary Session of the 32nd EORTC-NCI-AACR Symposium; Radiographically confirmed partial response after a month and a half on i.v. fadraciclib: MCL1-amplified endometrial cancer; failed seven lines of prior therapy; continuing treatment for more than 16 months with 96% reduction in target tumor lesions; High bioequivalence observed in 5 patients treated with oral fadraciclib; Enrolled 19 patients evaluating i.v. fadraciclib in combination with venetoclax in patients with relapsed or refractory AML/MDS and CLL with evidence of antileukemic activity; Enrolled five patients evaluating i.v. CYC140 in patients with advanced leukemias; Enrolled 12 patients in Phase 1/2 study evaluating an oral regimen of sapacitabine in combination with venetoclax in patients with relapsed or refractory AML/MDS; Announced peer-reviewed publication of a fadraciclib review in PLOS ONE. Authored by scientists from Cyclacel and The Institute of Cancer Research, London, the publication describes the discovery of fadraciclib and shows that its targeting of CDK2 and CDK9 leads to broad therapeutic potential Appointed Mark Kirschbaum, M.D. as Senior Vice President and Chief Medical Officer. Dr. Kirschbaum is a highly experienced hematologist/oncologist with over 30 years of experience in molecular medicine, new drug development, clinical trial design and patient care; Appointed Brian Schwartz, M.D, formerly CMO at ArQule, Inc., and Karin L. Walker, Chief Accounting Officer of Prothena Corporation plc, to the Board of Directors; Raised approximately $30 million in net cash in two equity financings and related warrant exercises providing estimated capital to early 2023. In 2021, Cyclacel will commence streamlined Phase 1/2 clinical studies, initially of oral fadraciclib and subsequently of oral CYC140, in a broad range of solid tumors and hematological malignancies. These studies are supported by fadraciclib's Phase 1 clinical data and its transcriptional mechanism of action enabling apoptosis of cancer cells and the extensive preclinical data of CYC140 demonstrating its antimitotic mechanism and broad therapeutic potential in several solid tumors and hematological malignancies. The clinical development plan for these studies calls for parallel evaluation of different schedules of the two agents in multiple cohorts defined by cancer histology and collection of biospecimens for translational analysis. The aim of these studies is to identify clinical activity which may lead to registration-enabling studies.
Cyclacel Pharmaceuticals announces $7M investment by Acorn Bioventures » 08:0912/2212/22/20
Cyclacel Pharmaceuticals announced it has entered into a definitive securities purchase agreement with Acorn Bioventures, LP, a biotech-focused fundamental investor. Under the agreement, Acorn Bioventures has agreed to purchase in a registered direct offering 485,912 shares of common stock and 237,745 shares of newly designated Series B Preferred Stock, and in a concurrent private placement, warrants to purchase 669,854 shares of common stock, for aggregate gross proceeds of approximately $7M. The offering is priced at-the-market pursuant to the rules of The Nasdaq Stock Market. The warrants will be exercisable beginning twelve months following the date of issuance, will expire on the five-year anniversary of the date of issuance, and have an exercise price of $4.13 per share. Cyclacel intends to use substantially all of the net proceeds of approximately $6.9M from the registered direct offering and concurrent private placement to rapidly advance clinical development of CYC140, a Polo-like-kinase 1 inhibitor.